Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,651 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia Spectrum and Other Psychotic Disorders Clear all
Completed Not applicable Interventional

Financial Incentives to Improve Medication Adherence

NCT04191876
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Depression
Interventions
Wellth - Financial Incentives
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 15, 2026, 1:23 AM EDT
Completed Not applicable Interventional Results available

Aerobic Exercise for Cognition in Schizophrenia

NCT02621983
View directory record Official record
Conditions
Schizophrenia
Interventions
Aerobic Exercise, Balance and Stretching
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 15, 2026, 1:23 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.

NCT01122927
View directory record Official record
Conditions
Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
23
States / cities
Dothan, Alabama • Downey, California • Miami, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 15, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Results available

A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules

NCT04567524
View directory record Official record
Conditions
Schizophrenia Schizoaffective
Interventions
LYN-005
Drug
Lead sponsor
Lyndra Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Long Beach, California • Atlanta, Georgia • Marlton, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 15, 2026, 1:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuropsychiatric Evaluation of Healthy Volunteers and Adults With Schizophrenia

NCT00001323
View directory record Official record
Conditions
Brain Injury, Dementia, Healthy, Mental Disorder, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
810 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 15, 2026, 1:23 AM EDT
Completed Not applicable Interventional Results available

Theta Burst Stimulation for Schizophrenia

NCT03288779
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Theta Burst Stimulation
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 15, 2026, 1:23 AM EDT
Completed No phase listed Observational

Antipsychotics and Blood Vessel Function

NCT00585273
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Not listed
Lead sponsor
Jess G. Fiedorowicz
Other
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 15, 2026, 1:23 AM EDT
Completed Phase 3 Interventional Results available

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

NCT00706654
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot, Placebo tablets
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
937 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
39
States / cities
Cerritos, California • Escondido, California • Garden Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 15, 2026, 1:23 AM EDT
Terminated Phase 2 Interventional Results available

Telmisartan Pilot Study on Treatment Resistant Schizophrenia

NCT03868839
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Treatment-resistant Schizophrenia
Interventions
Telmisartan Pill
Drug
Lead sponsor
Xiaoduo Fan
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 15, 2026, 1:23 AM EDT
Completed Phase 4 Interventional Results available

Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors

NCT00802919
View directory record Official record
Conditions
Schizophrenia, Cigarette Smoking
Interventions
Varenicline, Placebo for varenicline
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 15, 2026, 1:23 AM EDT
Completed Phase 4 Interventional

Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

NCT00090012
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Olanzapine, Quetiapine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
25
States / cities
Garden Grove, California • La Mesa, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 15, 2026, 1:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Modafinil on Brain Function in Patients With Schizophrenia

NCT00057707
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Modafinil, Functional MRI, Neuropsychological Testing
Drug · Procedure
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 15, 2026, 1:23 AM EDT
Completed Phase 3 Interventional

Open Label Extension Study of Bifeprunox

NCT00366171
View directory record Official record
Conditions
Schizophrenia
Interventions
Bifeprunox
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 66 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
83
States / cities
Little Rock, Arkansas • Anaheim, California • Boynton Beach, California + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Oct 15, 2026, 1:23 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

NCT07363577
View directory record Official record
Conditions
Schizophrenia
Interventions
LB-102 (50 mg tablet), LB-102 (100 mg tablet), Placebo
Drug · Other
Lead sponsor
LB Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
13
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 15, 2026, 1:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism

NCT02237417
View directory record Official record
Conditions
Schizophrenia
Interventions
Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 15, 2026, 1:23 AM EDT
Completed Phase 1 Interventional

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.

NCT04369391
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP363856 150 mg, Placebo, moxifloxacin 400 mg
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
Little Rock, Arkansas • Long Beach, California • Pico Rivera, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 15, 2026, 1:23 AM EDT
Completed Phase 3 Interventional Results available

A Study of Paliperidone Palmitate 6-Month Formulation

NCT03345342
View directory record Official record
Conditions
Schizophrenia
Interventions
PP6M, PP3M 350 mg eq., PP3M 525 mg eq., PP1M, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
25
States / cities
Rogers, Arkansas • Anaheim, California • Costa Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 15, 2026, 1:23 AM EDT
Completed Not applicable Interventional

What the Nose Knows: Hedonic Capacity, Psychosocial Interventions and Outcomes in Schizophrenia

NCT05282186
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive Enhancement Therapy, Social Skills Training
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 15, 2026, 1:23 AM EDT
Completed Phase 4 Interventional Results available

Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment

NCT00337350
View directory record Official record
Conditions
Schizophrenia
Interventions
rosiglitazone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 15, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Levetiracetam in Early Psychosis

NCT03129360
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder, Schizophreniform
Interventions
Levetiracetam, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 35 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 15, 2026, 1:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke

NCT00307203
View directory record Official record
Conditions
Tobacco-Use Disorder, Schizophrenia, Psychotic Disorders
Interventions
bupropion SR, Cognitive Behavioral Group Therapy, nicotine replacement therapy
Drug · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 15, 2026, 1:23 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Auditory Stimulation During Sleep on Brain Networks in Schizophrenia

NCT06386588
View directory record Official record
Conditions
Schizophrenia
Interventions
Closed loop auditory stimulation during sleep
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 15, 2026, 1:23 AM EDT
Withdrawn Phase 2 Interventional

L-arginine Study for Persistent Symptoms of Schizophrenia

NCT04054973
View directory record Official record
Conditions
Schizo Affective Disorder, Schizophrenia
Interventions
L-arginine, Sapropterin Dihydrochloride
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 15, 2026, 1:23 AM EDT
Completed Phase 2 Interventional

Schizophrenia Study In Adults

NCT00049946
View directory record Official record
Conditions
Schizophrenia
Interventions
talnetant, risperidone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
31
States / cities
Scottsdale, Arizona • Cerritos, California • Chula Vista, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 15, 2026, 1:23 AM EDT